FUTURE ONCOLOGY
Volume 6 #1/2 December 15, 2000
State-of-the-Art in the Management of Cancer
BLADDER CANCER-PART II
SCREENING, DIAGNOSIS, STAGING, AND FOLLOW-UP
Screening
Diagnosis and Follow-up
- In vitro Testing Approaches
- Urine cytology/cytopathology
- Bladder tumor antigen (BTA)
- Nuclear matrix proteins (NMP)
- Fibrin/fibrinogen degradation products (FDP)
- Telomerase
- p53 mutations and other genetic markers
- Cytokeratin
- Hyaluronic acid (HA) and hyaluronidase (HAase)
- Cystoscopy/Biopsy
Histopathology and Bladder Cancer Types
- Transitional Cell Carcinoma (TCC)
- Squamous Cell Carcinoma
- Adenocarcinoma
Stage and Grade
Technology Update
SYNTHETIC NUCLEIC ACID SEQUENCE CONSTRUCTS AS ONCOLOGY THERAPEUTICS - PART II
Types of Synthetic Nucleic Acid Constructs in Development as Oncology Therapeutics
- Antisense Oligos
- Triplex-Forming ODN (TFO)
- Catalytic Nucleic Acids/Ribozymes
- Hammerhead ribozymes
- Minizymes
- Maxizymes
- Hairpin ribozymes
- Snorbozymes
- Deoxyribozymes or DNA enzymes (DNAzymes)
- Dy-Tex ribozyme analogs
- Chimeric Nucleotides
- Intracellularly Produced Antisense RNA and DNA
- Aptamers
- Aptazymes
- Aptamers as diagnostics
Biological Activity of ODN
- CpG-containing ODN
- G-rich ODN
- ODN Conjugated to Radioisotopes
Clinical Considerations
- Toxicity
- Administration Route
- Oral delivery
- Pulmonary delivery
- Combination Therapy
|
